Oxford Events, the new replacement for OxTalks, will launch on 16th March. The two-week OxTalks freeze period starts on Monday 2nd March. During this time, there will be no facility to publish or edit events. The existing OxTalks site will remain available to view during this period. Once Oxford Events launches, you will need a Halo login to submit events. Full details are available on the Staff Gateway.
Type 2 diabetes (T2D) is a major cause of morbidity and mortality worldwide. Genome-wide association studies (GWAS) have revolutionized our understanding of the genetic underpinnings of T2D by detecting >600 associated loci, laying the groundwork for precision and personalized medicine. Integrating genomics into healthcare will improve individual risk prediction, tailor prevention programs, and optimize treatments based on a person’s unique genetic profile. Unfortunately, the mechanisms (e.g., target gene, functional variant, and direction of effect) by which the T2D-associated genetic variants influence T2D development are largely unknown, currently limiting the clinical utility of genetics and genomics. This presentation will cover current T2D-variant discovery efforts from the T2DGGI consortium, steady-state and context-specific variant-to-function efforts in pancreatic islets, and examples of how to incorporate genetic risk for T2D into public health and healthcare.
Bio : Following a PhD in Epidemiology at the University of Iowa, Cassie Spracklen worked as a Postdoctoral Fellow with Professor Karen Moelke at the University of North Carolina, Chapel Hill. In 2019 she was appointed to a tenure track position at the University of Massachusetts, Amherst. She has led several projects within the Asian Genetic Epidemiology Network (AGEN), and is currently co-lead of the fine-mapping working group within the Genetic Investigation of Anthropometric Traits (GIANT) consortium.
